Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer
Abstract.Liver metastases (LMs) are common in lung cancer.Despite substantial advances in diagnosis and treatment, the survival rate of patients with LM remains low as the immune-suppressive microenvironment of the liver allows tumor cells to evade the immune system.The impact of LMs on the Jacket outcomes of immune checkpoint inhibitors in patient